Clinical Policy: A Critical Issue in the Management of Adult Patients Presenting to the Emergency Department With Acute Carbon Monoxide Poisoning
Approved by the ACEP Board of Directors January 23, 2025

From the American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Carbon Monoxide Poisoning:

Richard D. Shih, MD (Writing Committee Chair)
Christian A. Tomaszewski, MD, MS, MBA
Amy Kaji, MD, MPH, PhD (Methodologist)
Deborah B. Diercks, MD, MSc (Committee Chair)
_____

Members of the American College of Emergency Physicians Clinical Policies Committee (Oversight Committee):

Deborah B. Diercks, MD, MSc (Co-Chair 2021-2022, Chair 2022-2024, Co-Chair 2024-2025)
Scott M. Silvers, MD (Co-Chair 2024-2025)
John D. Anderson, MD
Richard Byyny, MD, MSc (Methodologist)
Christopher R. Carpenter, MD, MSc
Benjamin W. Friedman, MD (Methodologist)
Seth R. Gemme, MD
Charles J. Gerardo, MD, MHS
Steven A. Godwin, MD
Benjamin W. Hatten, MD, MPH
Jason S. Haukoos, MD, MSc (Methodologist)
Heemun Kwok, MD, MS (Methodologist)
Bruce M. Lo, MD, MBA, RDMS
Sharon E. Mace, MD
Amal Mattu, MD
Susan B. Promes, MD, MBA
Kaushal H. Shah, MD
Richard D. Shih, MD
Andrea Slivinski, RN, DNP (ENA Representative 2021-2024)
Michael D. Smith, MD, MBA
Molly E. W. Thiessen, MD
John T. Thompson, MD (EMRA Representative 2023-2024)
Christian A. Tomaszewski, MD, MS, MBA
Stacy A. Trent, MD, MPH (Methodologist)
Jonathan H. Valente, MD
Lauren M. Westafer, DO, MPH, MS
Stephen P. Wall, MD, MSc, MAEd (Methodologist)
Yanling Yu, PhD (Washington Advocates for Patient Safety)
Michelle P. Lin, MD, MPH, MS (Liaison with the ACEP Quality and Patient Safety Committee and E-QUAL Steering Committee)
John T. Finnell, MD (Board Liaison 2020-2024)
Travis Schulz, MLS, AHIP, Staff Liaison, Clinical Policies Committee and Writing Committee on Carbon Monoxide Poisoning
Kaeli Vandertulip, MSLS, MBA, AHIP, Staff Liaison, Clinical Policies Committee

ABSTRACT

This clinical policy from the American College of Emergency Physicians addresses a key issue in the evaluation and management of adult patients presenting to the emergency department with acute carbon monoxide poisoning. A writing subcommittee conducted a systematic review of the literature to derive evidence-based recommendations to answer the following clinical question: In emergency department patients diagnosed with acute carbon monoxide poisoning, does hyperbaric oxygen therapy compared with normobaric (room pressure) oxygen therapy improve long-term neurocognitive outcomes? Evidence was graded, and recommendations were made based on the strength of the available data.

INTRODUCTION

Carbon monoxide (CO) is a clear, odorless gas that is a product of incomplete combustion of carbonaceous material. Carbon monoxide is one of the leading causes of poisoning with over a million cases of CO poisoning reported worldwide each year.[1] In the United States, CO poisoning is a leading cause of nonsuicidal poisoning deaths, with nearly 50,000 emergency department (ED) visits annually.[2,3]

The CO molecule binds to hemoglobin with a higher affinity than oxygen and can cause problems related to hypoxia. Without treatment, CO has an elimination half-life of approximately 5 hours.[4] In the presence of oxygen, this is decreased to 85 minutes and 20 minutes for high-flow nonrebreather mask and hyperbaric oxygen (HBO_2) therapy, respectively.[5]

In addition to the effects on hemoglobin, CO can cause a cascade of inflammatory and immunologic damage at the cellular level. Nitric oxide generation, free radical formation, lipid peroxidation, apoptosis, and immune mediated injury can occur.[6,7] These effects can lead to damage in almost every organ system; however, the most consequential are cardiac and neurologic.

Acute toxicity can cause a wide range of clinical effects, from mild headache or flu-like symptoms to chest pain, shortness of breath, myocardial infarction, dysrhythmia, confusion, altered mental status, and coma. Flu-like symptoms in occult cases of CO poisoning, especially during colder weather, further confound diagnosis.[8,9]

After the initial CO exposure, patients can develop new neurologic findings 2 to 40 days later.[10,11] These central nervous system abnormalities can range from problems in concentration and memory to seizures and Parkinson's-like syndrome. Virtually any neuropsychologic abnormality can be seen, including psychiatric ones like depression and psychosis. These late onset findings are called delayed neurologic sequelae (DNS). Risk factors for DNS include older age (≥36 years), higher CO level (≥25%), longer CO exposure interval (≥24 hours), loss of consciousness due to CO poisoning, low Glasgow Coma Score, low Mini-Mental Status Examination score, and

83   positive findings on brain computed tomography scans (general swelling, white matter and/or globus pallidus

84   abnormalities).[12,13]

85   The previous American College of Emergency Physicians (ACEP) clinical policy from 2017 addressed 3

86   critical questions[14]:

     1. In ED patients with suspected acute CO poisoning, can noninvasive carboxyhemoglobin

        measurement be used to accurately diagnose CO toxicity?

     2. In ED patients diagnosed with acute CO poisoning, does HBO_2 therapy, compared with

        normobaric oxygen (NBO) therapy, improve long-term neurocognitive outcomes?

     3. In ED patients diagnosed with acute CO poisoning, can cardiac testing be used to predict

        morbidity or mortality?

93   As a part of the revision process for this Clinical Policy, after a thorough literature search and review

94   process, it was determined that no new relevant studies were found regarding questions 1 and 3. These results will

95   be presented as a reaffirmation of the recommendations for these questions via revision and resubmission as separate

96   clinical policies.

97   The literature search for the HBO_2 versus NBO for DNS identified several new studies that met

98   methodologic criteria. This question of whether HBO_2 therapy can improve DNS outcomes in CO-poisoned patients

99   has been debated for several decades and remains hotly contested.[15] In the 2017 ACEP clinical policy, 5 randomized

100   controlled trials (RCTs) were identified that looked at this issue. Of the 5, 3 (1 Class II and 2 Class III) reported no

101   benefit from HBO_2 therapy, whereas the 2 others (both Class II studies) found improved DNS outcomes.[11,16-19]

102   In addition, there are more than 700 HBO_2 treatment facilities in the United States, with some states having

103   multiple locations and others without any.[20] Further, only a small proportion of these existing HBO_2 centers have

104   the equipment and staff necessary to treat high-acuity patients.[20] Transport for more than 50 miles for these patients

105   may be needed from many areas of the United States with the additional risks accompanying travel and possible

106   deterioration.[20-22]

107   Given the continued controversy for the use of HBO_2 to treat CO poisoning, this clinical policy will revisit

108   the issue, reviewing the eligible published literature since the recommendation made in the 2017 clinical policy.

109

110   **METHODOLOGY**

This ACEP clinical policy was developed by emergency physicians with input from medical librarians and a patient safety advocate; is based on a systematic review and critical, descriptive analysis of the medical literature; and is reported in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines.[23]

Search and Study Selection

This clinical policy is based on a systematic review with critical analysis of the medical literature meeting the inclusion criteria. Searches of PubMed, SCOPUS, Embase, Web of Science, and the Cochrane Database of Systematic Reviews were performed by a second librarian. Search terms and strategies were peer reviewed by a second librarian. All searches were limited to human studies published in English. Specific key words/phrases, years used in the searches, dates of searches, and study selection are identified under the critical question. In addition, relevant articles from the bibliographies of included studies and more recent articles identified by committee members and reviewers were included.

Using Covidence (Covidence, Melbourne, Australia), 2 subcommittee members independently reviewed the identified abstracts to assess for possible inclusion. Of those identified for potential inclusion, each full-length text was reviewed for eligibility. Those identified as eligible were subsequently abstracted and forwarded to the committee's methodology group (emergency physicians with specific research methodological expertise) for methodological grading using a Class of Evidence framework (Appendix E1, available at http://www.annemergmed.com).

Assessment of Risk of Bias and Determination of Classes of Evidence

Each study identified as eligible by the subcommittee was independently graded by 2 methodologists. Design 1 represents the strongest possible study design to answer the critical question, which relates to whether the focus was therapeutic, diagnostic, prognostic, or a meta-analysis. Subsequent design types (ie, Design 2 and Design 3) represent respectively weaker study designs. Articles are then graded on dimensions related to the study's methodological features and execution, including but not limited to randomization processes, blinding, allocation concealment, methods of data collection, outcome measures and their assessment, selection, and misclassification

4

139 biases, sample size, generalizability, data management, analyses, congruence of results and conclusions, and

140 potential for conflicts of interest.

141   Using a predetermined process that combines the study's design, methodological quality, and applicability

142 to the critical question, 2 methodologists independently assigned a preliminary Class of Evidence grade for each

143 article. Articles with concordant grades from both methodologists received that grade as their final grade. Any

144 discordance in the preliminary grades was adjudicated through discussion which involved at least 1 additional

145 methodologist, resulting in a final Class of Evidence assignment (ie, Class I, Class II, Class III, or Class X)

146 (Appendix E2, available at http://www.annemergmed.com). Studies identified with significant methodologic

147 limitations and/or ultimately determined to not be applicable to the critical question received a Class of Evidence

148 grade "X" and were not used in formulating recommendations for this policy. However, content in these articles

149 may have been used to formulate the background and to inform expert consensus in the absence of evidence. Classes

150 of evidence grading may be found in the Evidentiary Table included at the end of this policy.

151

152 **Translation of Classes of Evidence to Recommendation Levels**

153   Based on the strength of evidence for each critical question, the subcommittee drafted the recommendations

154 and supporting text, synthesizing the evidence using the following guidelines:

155   *Level A recommendations.* Generally accepted principles for patient care that reflect a high degree of

156 scientific certainty (eg, based on evidence from 1 or more Class of Evidence I or multiple Class of Evidence II

157 studies that demonstrate consistent effects or estimates).

158   *Level B recommendations.* Recommendations for patient care that may identify a particular strategy or

159 range of strategies that reflect moderate scientific certainty (eg, based on evidence from 1 or more Class of Evidence

160 II studies or multiple Class of Evidence III studies that demonstrate consistent effects or estimates).

161   *Level C recommendations.* Recommendations for patient care that are based on evidence from Class of

162 Evidence III studies or, in the absence of adequate published literature, based on expert consensus. In instances

163 where consensus recommendations are made, "consensus" is placed in parentheses at the end of the

164 recommendation.

165   There are certain circumstances in which the recommendations stemming from a body of evidence should

166   not be rated as highly as the individual studies on which they are based. Factors such as consistency of results,

167   uncertainty of effect magnitude, and publication bias, among others, might lead to a downgrading of

168   recommendations. When possible, clinically oriented statistics (eg, likelihood ratios [LRs], number needed to treat

169   [NNT]) are presented to help the reader better understand how the results may be applied to the individual patient.

170   This can assist the clinician in applying the recommendations to most patients but allow adjustment when applying

171   to patients with extremes of risk (Appendix E3, available at http://www.annemergmed.com).

172

Evaluation and Review of Recommendations

174   Once drafted, the policy was distributed for internal review (by members of the entire committee), followed

175   by external expert review and an open comment period for all ACEP membership. Comments were received during

176   a 30-day open comment period, with notices of the comment period sent electronically to ACEP members,

177   published in *EM Today*, posted on the ACEP website, and sent to other pertinent physician organizations. The

178   responses were used to further refine and enhance this clinical policy, although responses do not imply endorsement.

179   Clinical policies are scheduled for revision every 3 years; however, interim reviews are conducted when technology,

180   methodology, or the practice environment changes significantly.

181

Application of the Policy

183   This policy is not intended to be a complete manual on the evaluation and management of adult patients

184   with CO poisoning but rather a focused examination of a critical question that has particular relevance to the current

185   practice of emergency medicine. Potential benefits and harms of implementing recommendations are briefly

186   summarized within the critical question.

187   It is the goal of the Clinical Policies Committee to provide evidence-based recommendations when the

188   scientific literature provides sufficient quality information to inform recommendations for the critical question. In

189   accordance with ACEP Resolution 56(21), ACEP clinical policies do not use race-based calculators in the

190   formulation of the recommendations. When the medical literature does not contain adequate empirical data to

191 inform a critical question, the members of the Clinical Policies Committee believe that it is equally important to

192 alert emergency physicians to this fact.

193   This clinical policy is not intended to represent a legal standard of care for emergency physicians.

194 Recommendations offered in this policy are not intended to represent the only diagnostic or management options

195 available to the emergency physician. ACEP recognizes the importance of the individual physician's judgment and

196 patient preferences. This guideline provides clinical strategies for which medical literature exists to inform the

197 critical question addressed in this policy. ACEP funded this clinical policy.

198
199   ***Scope of Application.*** This guideline is intended for physicians working in EDs.

200   ***Inclusion Criteria.*** This guideline is intended for adult patients presenting to the ED with suspected or

201 diagnosed acute CO poisoning.

202   ***Exclusion Criteria.*** This guideline is not intended to be used for out-of-hospital emergency care patients,

203 pediatric populations, pregnant patients and fetal exposures, those with chronic CO poisoning, or patients with

204 delayed presentations (more than 24 hours after cessation of exposure) of CO poisoning.

205
206 **CRITICAL QUESTION**
207
208 **In ED patients diagnosed with acute CO poisoning, does HBO$_2$ therapy, compared with normobaric oxygen**
209 **therapy, improve long-term neurocognitive outcomes?**
210
211   **Patient Management Recommendations**

212   ***Level A recommendations.*** *None specified.*

213   ***Level B recommendations.*** *None specified.*

214   ***Level C recommendations.*** In symptomatic CO poisoning, selected patients may benefit from HBO$_2$

215 treatment based on severity of symptoms and availability (distance and time).

216
217   Potential Benefit of Implementing the Recommendations:
218   • Improved neurologic outcomes.
219
220   Potential Harm of Implementing the Recommendations:
221   • Hyperbaric induced middle ear barotrauma.
222   • Oxygen toxicity (seizure).
223   • Risks and costs associated with transport to a hyperbaric chamber.
224   • Clinical deterioration during transport.
225   • Need for significant (>50 miles) travel to a hyperbaric chamber.
226   • Chamber induced claustrophobia.

227
228   Key words/phrases for literature searches: Carbon Monoxide Intoxication, Carbon Monoxide Poisoning,
229 Hyperbaric Oxygen, Hyperbaric Oxygen Therapy, Hyperbaric Oxygenation, Normobaric Oxygen Therapy, and
230 variations and combinations of keywords/phrases. Searches included January 2015 to search dates of August 26,
231 2022, and April 12, 2024 (Appendix E4, available at http://www.annemergmed.com).
232
233   Study Selection: Eight hundred fifty articles were identified in the searches. Three hundred eighty articles
234 were selected from the search results as candidates for further review. After grading for methodological rigor, 0
235 Class I studies, 0 Class II studies, and 4 Class III studies were included for this critical question (Appendix E5,
236 available at http://www.annemergmed.com).
237

238   Since the publication of the 2017 ACEP CO clinical policy, 8 new studies were identified that addressed

239 this critical question. Four of these studies were rated as Class III, whereas the others were rated as Class X due to

240 methodologic flaws or inability to directly attest to the question.[14,24-27] Among the 4 manuscripts that met inclusion

241 criteria, 3 were meta-analyses that included data that was predominantly made up of the 5 RCTs that were included

242 in the 2017 clinical policy.[25-27] Because of this, the writing committee decided to include these earlier 5 pivotal

243 RCTs in the current analysis.[11,16-19]

244   Of the 5 RCTs that were included in the 2017 clinical policy, 3 were graded as Class II and 2 as Class

245 III.[11,16-19] All of these studies randomized patients to either treatment with HBO_2 or NBO and their main outcome

246 measure was neurologic sequelae at follow-up, the topic of this critical question. Two of the studies, both Class II,

247 showed improved long-term neurologic outcome with HBO_2, and the other 3, 1 Class II and 2 Class III, showed no

248 significant effect.[11,16-19]

249   Although all 5 studies randomized CO exposed patients to HBO_2 and NBO, many other important variables

250 differed.[11,16-19] Animal studies suggest that HBO_2 treatments are effective when started early, with improved

251 biochemical response as dose increases up to 3.0 atmospheres (ATA).[28] Multiple retrospective studies show that

252 early HBO_2 (within several hours post exposure) versus late exposure led to better neurologic outcomes.[29,30] Further,

253 syncope is a strong predictor of poor neurologic outcome.[31] These 5 RCTs varied greatly in all of these variables:

254 inclusion when exposure occurred more than 6 hours, exclusion of comatose patients, and utilization of many

255 different HBO_2 treatment variables, including pressures less than 2.5 ATA (see Table 1).[11,16-19] In addition, studies

256 differed in blinding techniques. One study utilized sham HBO_2 treatments (graded Class II, HBO_2 beneficial), and

257 other studies did not blind evaluators when assessing neurologic sequelae.

258

259 **Table 1.** Treatment variables of RCTs informing 2017 clinical policy recommendation.

Study	Time to HBO$_2$ Per Protocol (h)	Time to HBO$_2$ (mean)	Mean Age (y)	No. Of Subjects	Male	Initial HBO$_2$ Dose	Sham Control	Follow-up Assessment (blinded)	Suicide	Syncope	Outcome Favors HBO$_2$
Annane et al[18] (2011)	<12	<12 h	33.0	179	41%	2 ATA 2 h	NO	1 mo (YES)	0%	97%	NO
Raphael et al[16] (1989)	<12	7.1 h	35.4	343	49%	2 ATA 2 h	NO	1 mo (NO)	n/a	n/a	NO
Scheinkestel et al[17] (1999)	No Limit	7.1 h	36.3	191	81%	2.8 ATA 1 h	NO	1 mo (YES)	69%	53%	NO
Thom et al[11] (1995)	<6	2 h	37.0	65	52%	2.8 ATA 0.5 h then 2.0 ATA 90 min	NO	4 wk (NO)	n/a	n/a	YES
Weaver et al[19] (2002)	<24	5.6 h	35.5	152	71%	3 ATA 1 h then 2 ATA 1 h	YES	6 wk 6 mo, 12 mo (YES)	31%	53%	YES

260

261   Because of these many differences, all the RCTs have been criticized in the literature for not being designed

262 properly to assess HBO$_2$'s ability or inability to prevent DNS.[32-36] Because the findings of these RCTs have been

263 equivocal with regards to HBO$_2$ efficacy, consensus has accordingly been difficult to reach.[14,32-34,37]

264   Of the 4 studies identified since the 2017 ACEP clinical policy, only 1 is not a meta-analysis.[24-27] This

265 study, by Nakajima et al,[24] is a retrospective study that utilized data from a nationwide inpatient database in Japan.

266 The study included 2,034 patients, all CO-poisoned and ill enough to require hospital admission. All patients

267 received HBO$_2$ and were compared with a propensity-matched control group that did not receive HBO$_2$. For hospital

268 mortality, the HBO$_2$ group was unchanged, but earlier discharge, a lower proportion of depressed mental status

269 (NNT 42; difference -3.2%, 95% CI -4.9% to -1.5%) and improvement in activities of daily living (NNT 41;

270 difference -5.3%, 95% CI -7.8% to -2.7%) were seen in the group receiving HBO$_2$ compared with the control group.

271 Limitations included retrospective design, lack of long-term outcome beyond 7 days, and no standardization of

272 HBO$_2$ therapy protocols, with some centers only using as little as 2.0 ATA of HBO$_2$ for as little as 60 minutes. With

273 almost a quarter of subjects having some medical problems at discharge, primarily with activities of daily living,

274 this study supports a modest benefit of HBO$_2$ treatment.

275   The other 3 studies, all Class III, were meta-analyses of previously considered data (2017 ACEP CO Policy)

276   (Table 2).[14,25-27] The first, Ho et al,[25] was a network meta-analysis of 8 prior studies (N=1,785) looking at the effects

277   of HBO_2 on mortality and neurologic outcomes after CO poisoning. However, 3 of the 8 RCTs (Ducasse et al[38]

278   1995; Annane et al[39] 2001; and Hampson et al[40] 2006) received X grades by ACEP Clinical Policies Committee

279   methodologists. Six studies specifically looked at the effect of NBO versus single HBO_2 treatment found no

280   difference in any meaningful outcome: mortality (3 studies: Raphael et al[16] 1989; Scheinkestel et al[17] 1999; and

281   Annane et al[18] 2011), headache improvement (4 studies: Thom et al[11] 1995; Raphael et al[16] 1989; Ducasse et al[38]

282   1995; and Annane et al[39] 2001) and general fatigue (2 studies: Raphael et al[16] 1989 and Annane et al[18] 2011). The

283   most important outcomes, factors potentially related to DNS, were provided by 3 studies (Raphael et al[16] 1989;

284   Annane et al[18] 2011; and Weaver et al[19] 2002). When pooled, there was no difference in relative risk of memory

285   impairment or concentration impairment between the NBO and HBO_2 groups. One criticism may be that not enough

286   HBO_2 treatments were administered, but the included Annane et al[18] (2011) study showed that additional treatments

287   (up to 3 total) led to potentially worse outcomes in memory and concentration. Further, only 1 of the 8 included

288   studies blinded investigators to the treatments.[19] The authors conclude that HBO_2 may not be an effective treatment

289   for patients with CO poisoning.

290

291   **Table 2.** Summary of studies included in the 3 meta-analyses (only listed studies that had an NBO control group
292   for comparison).

Study	Lin et al[26] (2018)	Wang et al[27] (2019)	Ho et al[25] (2022)	ACEP[14] (2017) Rating	Outcome Favors HBO_2
Annane et al[39] (2001)	-	-	✓	X	NO
Annane et al[18] (2011)	✓	✓	✓	III	NO
Ducasse et al[38] (1995)	✓	✓	✓	X	YES
Mathieu et al[41] (1996)	-	✓	-	X	NO
Raphael et al[16] (1989)	✓	✓	✓	III	NO
Scheinkestel et al[17] (1999)	✓	✓	✓	II	NO
Thom et al[11] (1995)	✓	✓	✓	II	YES
Weaver et al[19] (2002)	✓	✓	✓	II	YES
Hampson et al[40]	-	-	✓	X	N/A

(2006)					

A second meta-analysis of 6 RCTs, Lin et al,[26] looked at the effect of NBO versus HBO$_2$ on neuropsychiatric outcome. One (Ducasse et al[38] 1995) of the 6 RCTs received Class X grade from the ACEP Clinical Policies Committee methodologists (see Table 1). The effects included any or all of the following: headache, memory impairment, difficulty concentrating, disturbed sleep, asthenia, or any other form of DNS. Compared with the NBO group, the HBO$_2$ patients had a lower percentage of almost all adverse neurologic sequelae. Most importantly, the patients in the HBO$_2$ group had less DNS (25% versus 31.1%, risk ratio 0.35; 95% CI 0.02 to 5.97). Although the overall HBO$_2$ group had better outcomes, most of the 95% CI overlapped, suggesting any benefit may be random or modest. However, the HBO$_2$ group showed statistically significant benefit in memory impairment and difficulties in concentrating. As with the previous meta-analysis, all the studies except 1 lacked blinding. Overall, this study showed modest benefit from HBO$_2$ treatment.

The final Class III study, Wang et al,[27] added a seventh RCT study (Mathieu et al[41] 1996) to the metanalysis. Two of the 7 included studies received Class X grades by the ACEP Clinical Policies Committee methodologists.[39,40] With a total of 2,023 patients diagnosed with CO poisoning, the authors concluded that HBO$_2$ compared with NBO, was not associated with any improved outcomes regarding mortality, recovery, neurologic sequelae, asthenia, or headache. For 1 outcome, memory impairment, the data did show, with data available from only 5 cohorts, that HBO$_2$ was associated with a lower risk of memory impairment (risk ratio 0.67; 95% CI 0.46 to 0.97). The authors also mentioned that 2 HBO$_2$ sessions, based on a single study (Anane et al[18] 2011), did not show additional benefit. Potential limitations include the fact that the outcome measures were within a short time frame and may not be sustained.

Summary

Since publication of the 2017 ACEP clinical policy on CO treatment with HBO$_2$, only 4 new studies were identified that met methodological quality for inclusion in answering this critical question.[14] Of these studies, only 1 had original data, but this was a retrospective propensity-matched trial and showed only modest benefit.[24] The 3 meta-analyses included varying numbers of the same RCT studies that were graded and discussed in the previous ACEP clinical policy on addressing acute CO poisoning.[14] In all but 1 of the RCTs (Weaver et al[19] 2002), patients

11

320 were not blinded, but more importantly, the control NBO groups did not get standardized treatment to ensure 100%

321 oxygen was continuously delivered. Based on this review, the Clinical Policies Committee's conclusions are similar

322 to those made in the 2017 clinical policy that HBO_2 may provide a modest benefit, especially in memory

323 impairment.

324

325 **Future Research**

326 The efficacy of HBO_2 treatment to prevent DNS from CO poisoning remains controversial, with studies

327 having equivocal findings. These differences in results may be due to differences in methodology such as lack of

328 blinding, poor follow-up, timing of HBO_2 treatment, differing inclusion criteria, HBO_2 dose, number of HBO_2

329 treatments, lack of critically ill patients, and outcome measures (see Table 2). Future studies need to look at timing

330 of HBO_2 initiation and perhaps targeting those CO-poisoned patients most at risk for DNS.[12] As many of the past

331 studies use different inclusion criteria, treatment, and outcomes, there is a need for interested researchers to meet

332 and agree on standard methodology for future RCTs.

333

334 *Relevant industry relationships: There were no relevant industry relationships disclosed by the*
335 *subcommittee members for this topic.*
336 *Relevant industry relationships are those relationships with companies associated with products or*
337 *services that significantly influence the specific aspect of disease addressed in the critical question.*
338

REFERENCES

1. Mattiuzzi C, Lippi G. Worldwide epidemiology of carbon monoxide poisoning. *Hum Exp Toxicol*. 2020;39:387-392.

2. Sircar K, Clower J, Shin MK, et al. Carbon monoxide poisoning deaths in the United States, 1999 to 2012. *Am J Emerg Med*. 2015;33:1140-1145.

3. Shin M, Bronstein AC, Glidden E, et al. Morbidity and mortality of unintentional carbon monoxide poisoning: United States 2005 to 2018. *Ann Emerg Med*. 2023;81:309-317.

4. Peterson JE, Stewart RD. Absorption and elimination of carbon monoxide by inactive young men. *Arch Environ Health*. 1970;21:165-171.

5. Weaver LK, Howe S, Hopkins R, et al. Carboxyhemoglobin half-life in carbon monoxide-poisoned patients treated with 100% oxygen at atmospheric pressure. *Chest*. 2000;117:801-808.

6. Thom SR. Carbon monoxide-mediated brain lipid peroxidation in the rat. *J Appl Physiol (1985)*. 1990;68:997-1003.

7. Hardy KR, Thom SR. Pathophysiology and treatment of carbon monoxide poisoning. *J Toxicol Clin Toxicol*. 1994;32:613-629.

8. Dolan MC, Haltom TL, Barrows GH, et al. Carboxyhemoglobin levels in patients with flu-like symptoms. *Ann Emerg Med*. 1987;16:782-786.

9. Ng PC, Long B, Koyfman A. Clinical chameleons: an emergency medicine focused review of carbon monoxide poisoning. *Intern Emerg Med*. 2018;13:223-229.

10. Choi IS. Delayed neurologic sequelae in carbon monoxide intoxication. *Arch Neurol*. 1983;40:433-435.

11. Thom SR, Taber RL, Mendiguren II, et al. Delayed neuropsychologic sequelae after carbon monoxide poisoning: prevention by treatment with hyperbaric oxygen. *Ann Emerg Med*. 1995;25:474-480.

12. Weaver LK, Valentine KJ, Hopkins RO. Carbon monoxide poisoning: risk factors for cognitive sequelae and the role of hyperbaric oxygen. *Am J Respir Crit Care Med*. 2007;176:491-497.

13. Ku HL, Yang KC, Lee YC, et al. Predictors of carbon monoxide poisoning-induced delayed neuropsychological sequelae. *Gen Hosp Psychiatry*. 2010;32:310-314.

14. American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Carbon Monoxide Poisoning, Wolf SJ, Maloney GE, Shih RD, et al. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute carbon monoxide poisoning. *Ann Emerg Med*. 2017;69:98-107.

15. Seger D, Welch L. Carbon monoxide controversies: neuropsychologic testing, mechanism of toxicity, and hyperbaric oxygen. *Ann Emerg Med*. 1994;24:242-248.

16. Raphael JC, Elkharrat D, Jars-Guincestre MC, et al. Trial of normobaric and hyperbaric oxygen for acute carbon monoxide intoxication. *Lancet*. 1989;2:414-419.

17. Scheinkestel CD, Bailey M, Myles PS, et al. Hyperbaric or normobaric oxygen for acute carbon monoxide poisoning: a randomised controlled clinical trial. *Med J Aust*. 1999;170:203-210.

393   18. Annane D, Chadda K, Gajdos P, et al. Hyperbaric oxygen therapy for acute domestic carbon monoxide
394   poisoning: two randomized controlled trials. *Intensive Care Med*. 2011;37:486-492.
395

396   19. Weaver LK, Hopkins RO, Chan KJ, et al. Hyperbaric oxygen for acute carbon monoxide poisoning. *N Engl J*
397   *Med*. 2002;347:1057-1067.
398

399   20. Chin W, Jacoby L, Simon O, et al. Hyperbaric programs in the United States: locations and capabilities of
400   treating decompression sickness, arterial gas embolisms, and acute carbon monoxide poisoning: survey results.
401   *Undersea Hyperb Med*. 2016;43:29-43.
402

403   21. Sloan EP, Murphy DG, Hart R, et al. Complications and protocol considerations in carbon monoxide-poisoned
404   patients who require hyperbaric oxygen therapy: report from a ten-year experience. *Ann Emerg Med*.
405   1989;18:629-634.
406

407   22. Bosco G, Garetto G, Rubini A, et al. Safety of transport and hyperbaric oxygen treatment in critically-ill patients
408   from Padua hospitals into a centrally-located, stand-alone hyperbaric facility. *Diving Hyperb Med*.
409   2016;46:155-159.
410

411   23. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting
412   systematic reviews. *BMJ*. 2021;372:n71.
413

414   24. Nakajima M, Aso S, Matsui H, et al. Hyperbaric oxygen therapy and mortality from carbon monoxide
415   poisoning: a nationwide observational study. *Am J Emerg Med*. 2020;38:225-230.
416

417   25. Ho YW, Chung PY, Hou SK, et al. Should we use hyperbaric oxygen for carbon monoxide poisoning
418   management? A network meta-analysis of randomized controlled trials. *Healthcare (Basel)*. 2022;10:1311.
419

420   26. Lin CH, Su WH, Chen YC, et al. Treatment with normobaric or hyperbaric oxygen and its effect on
421   neuropsychometric dysfunction after carbon monoxide poisoning: a systematic review and meta-analysis of
422   randomized controlled trials. *Medicine (Baltimore)*. 2018;97:e12456.
423

424   27. Wang W, Cheng J, Zhang J, et al. Effect of hyperbaric oxygen on neurologic sequelae and all-cause mortality
425   in patients with carbon monoxide poisoning: a meta-analysis of randomized controlled trials. *Med Sci Monit*.
426   2019;25:7684-7693.
427

428   28. Thom SR. Functional inhibition of leukocyte B2 integrins by hyperbaric oxygen in carbon monoxide-mediated
429   brain injury in rats. *Toxicol Appl Pharmacol*. 1993;123:248-256.
430

431   29. Lee Y, Cha YS, Kim SH, et al. Effect of hyperbaric oxygen therapy initiation time in acute carbon monoxide
432   poisoning. *Crit Care Med*. 2021;49:e910–e919.
433

434   30. Choi S, Nah S, Han S. Correlation between time to hyperbaric oxygen therapy and delayed neurological
435   sequelae in acute carbon monoxide poisoning patients. *Diagnostics (Basel)*. 2024;14:186.
436

437   31. Rose JJ, Zhang MS, Pan J, et al. Heart-Brain score: the development and validation of a simple mortality
438   prediction score for carbon monoxide poisoning utilizing deep learning. *Clin Toxicol (Phila)*. 2023;61:492-499.
439

440   32. Buckley NA, Juurlink DN, Isbister G, et al. Hyperbaric oxygen for carbon monoxide poisoning. *Cochrane*
441   *Database Syst Rev*. 2011;2011:CD002041.
442

443   33. Sethuraman K, Thom SR. Hyperbaric oxygen should be used for carbon monoxide poisoning. *Br J Clin*
444   *Pharmacol*. 2023;89:939-941.
445

34. Juurlink DN. Hyperbaric oxygen should not be used routinely for carbon monoxide poisoning. *Br J Clin Pharmacol*. 2023;89:942-945.

35. Freytag DL, Schiefer JL, Beier JP, et al. Hyperbaric oxygen treatment in carbon monoxide poisoning - does it really matter? *Burns*. 2023;49:1783-1787.

36. Paganini M, Thom SR. Editorial: carbon monoxide poisoning: updates on prevention, diagnosis, and treatment. *Front Med (Lausanne)*. 2024;11:1411547.

37. Chiew AL, Buckley NA. Carbon monoxide poisoning in the 21st century. *Crit Care*. 2014;18:221.

38. Ducasse JL, Celsis P, Marc-Vergnes JP. Non-comatose patients with acute carbon monoxide poisoning: Hyperbaric or normobaric oxygenation? *Undersea Hyperb. Med*. 1995;22:9-15.

39. Annane D, Chevret S, Jars-Guincestre C, et al. Prognostic factors in unintentional mild carbon monoxide poisoning. *Intensive Care Med*. 2001;27:1776-1781.

40. Hampson NB, Dunford RG, Ross, DE, et al. A prospective, randomized clinical trial comparing two hyperbaric treatment protocols for carbon monoxide poisoning. *Undersea Hyperb Med*. 2006;33:27-32.

41. Mathieu D, Wattel F, Mathieu-Nolf M, et al. Randomized prospective study comparing the effect of HBO versus 12 hours of NBO in non comatose CO poisoned patients: results of the interim analysis [abstract]. 1996. Undersea and Hyperbaric Medical Society Annual Meeting Abstracts. Accessed July 26, 2024. https://www.uhms.org/uhm-search/uhm-journal-volume-23/supplement-1996/supplement-1996.html.

470 **Appendix E1.** Literature classification schema.*

Design/Class	Therapy[†]	Diagnosis[‡]	Prognosis[§]
1	Randomized, controlled trial or meta-analysis of randomized trials	Prospective cohort using a criterion standard or meta-analysis of prospective studies	Population prospective cohort or meta-analysis of prospective studies
2	Nonrandomized trial	Retrospective observational	Retrospective cohort Case control
3	Case series	Case series	Case series

471 *Some designs (eg, surveys) will not fit this schema and should be assessed individually.
472 [†]Objective is to measure therapeutic efficacy comparing interventions.
473 [‡]Objective is to determine the sensitivity and specificity of diagnostic tests.
474 [§]Objective is to predict outcome, including mortality and morbidity.
475

476 **Appendix E2.** Approach to downgrading strength of evidence.
477 _____
478
479   **Design/Class**
480   _____

Downgrading	1	2	3
None	I	II	III
1 level	II	III	X
2 levels	III	X	X
Fatally flawed	X	X	X

487
488
489 **Appendix E3.** Likelihood ratios and number needed to treat.*
490

LR (+)	LR (−)	
1.0	1.0	Does not change pretest probability
1–5	0.5–1	Minimally changes pretest probability
10	0.1	May be diagnostic if the result is concordant with pretest probability
20	0.05	Usually diagnostic
100	0.01	Almost always diagnostic even in the setting of low or high pretest probability

491 *LR*, likelihood ratio.
492 *Number needed to treat (NNT): number of patients who need to be treated to achieve 1
493 additional good outcome; NNT=1/absolute risk reduction×100, where absolute risk reduction is the risk
494 difference between 2 event rates (ie, experimental and control groups).
495

Appendix E4. Preferred Reporting Items for Systematic Reviews and Meta-Analysis flow diagrams.[23]

Appendix E5. Literature searches.

Search Date	Database	Search Strings	Filters
8/26/2022 and 4/12/2024	PubMed	((carbon monoxide poisoning[tiab]) OR (carbon monoxide intoxication[tiab]) OR (Carbon Monoxide Poisoning[Mesh])) AND ((hyperbaric oxygenation[tiab]) OR (hyperbaric oxygen therap*) OR (Hyperbaric Oxygenation[Mesh]) OR (normobaric oxygen therap*[tiab]))	2015 to search date
8/26/2022 and 4/12/2024	Scopus	TITLE-ABS-KEY ("carbon monoxide poisoning" OR "carbon monoxide intoxication") AND TITLE-ABS-KEY ("hyperbaric oxygen" OR "hyperbaric oxygen therap*" OR "normobaric oxygen therap*")	2015 to search date
8/26/2022 and 4/12/2024	Embase	('carbon monoxide poisoning':ti,ab,kw OR 'carbon monoxide intoxication':de,ti,ab,kw) AND ('hyperbaric oxygenation':ti,ab,kw OR 'hyperbaric oxygen therap*':de,ti,ab,kw)	2015 to search date
8/26/2022 and 4/12/2024	Web of Science	TS=("carbon monoxide poisoning" OR "carbon monoxide intoxication") AND TS=("hyperbaric oxygen" OR "hyperbaric oxygen therap*" OR "normobaric oxygen therap*")	2015 to search date
8/26/2022 and 4/12/2024	Cochrane Library	("carbon monoxide poisoning":ti,ab,kw OR "carbon monoxide intoxication":ti,ab,kw) AND ("hyperbaric oxygenation":ti,ab,kw OR "hyperbaric oxygen therap*":ti,ab,kw)	2015 to search date

Evidentiary Table.

Author & Year Published	Class of Evidence	Setting & Study Design	Methods & Outcome Measures	Results	Limitations & Comments
Nakajima et al[24] (2020)	III	Analysis of the Japanese administrative database including data from >1,000 acute care hospitals and approximately 90% of all tertiary care emergency hospitals in the country; the database includes data on level of alertness and ADLs at discharge	Included patients had a main diagnosis of carbon monoxide poisoning and were discharged between April 2010 and March 2017; patients were excluded for cardiac arrest within 1 day of admission, discharge within 1 day of admission, those who were readmitted to the hospital, those with a high burn index ≥10, and use of intra-aortic balloon pump or extracorporeal life support; patients who received HBO_2 within 1 day of hospital admission were compared to those who did not; the relevant outcomes for this analysis were a depressed mental status at hospital discharge, as reported using the Japanese Coma Score, a 4 level instrument (alert, not fully alert but awake without stimuli, arousable with stimulation, and coma) and decreased ADLs, as measured using the Barthel Index; a propensity score analysis was used to compare those who did and did not receive hyperbaric oxygen	4,068 propensity score matched patients provided data on depressed mental status at discharge; depressed mental status was less likely among patients who received HBO_2 (between group difference -2.3%, 95% CI -3.8% to -0.9%, P=.002, NNT=42); 3,729 propensity score matched patients provided data on reduced ADLs at discharge; reduced ADLs at discharge was less likely among patients who received HBO_2 (between group difference -2.4%, 95% CI -4.7% to -0.2%, P=.035, NNT=41)	Starts as Design II for prognostic questions with one level downgrade for unblinded and unreliable measurement of outcomes; propensity score matching was used to create similar comparison groups (HBO_2 versus no HBO_2) though this tool only accounts for known and measured confounders; protocols for HBO_2 were not standardized

Evidentiary Table (continued).

Author & Year Published	Class of Evidence	Setting & Study Design	Methods & Outcome Measures	Results	Limitations & Comments
Ho et al[25] (2022)	III	Network meta-analysis (registered PROSPERO) 8 studies contributed (7 to meta-analysis and 1 to qualitative synthesis) of RCTs comparing HBO_2 versus NBO and 1 session versus 2 sessions HBO_2	Inclusion criteria: RCTs of HBO_2; outcomes analyzed: mortality, headache recovery, fatigue, memory impairment, and difficulty with concentration; excluded non-RCTs and gray literature without details of trial design; funnel plot and Egger's regression intercept used to assess publication bias	N=1,785 patients; 8 studies reported no difference in HBO_2 versus NBO and noted that 2 session HBO_2 fared worse than 1 session HBO_2 for fatigue RR 1.80 (95% CI 1.01 to 3.19) and impaired concentration RR 1.85 (95% CI 1.19 to 2.89); 7 of 8 studies were at high risk for bias for participant and study personnel blinding, but 5 of 8 studies were at low risk for bias for sequence generation, allocation concealment, and selective reporting	Starts as Design I, but quality of individual studies not adequately described; 7 of 8 studies at high risk for bias due to participant and personnel blinding with no sensitivity analysis or regression analysis to account for it; though memory and concentration are measures of neurocognitive outcome, mortality and headache are not

Evidentiary Table (continued).

Author & Year Published	Class of Evidence	Setting & Study Design	Methods & Outcome Measures	Results	Limitations & Comments
Lin et al[26] (2018)	III	Meta-analysis of RCT's comparing the effects of NBO to HBO_2 on neuropsychiatric outcomes	Inclusion criteria: RCTs of HBO_2; outcomes of headache recovery, fatigue, memory impairment, and difficulty with concentration; excluded non-RCT; funnel plot and Egger's regression intercept used to assess publication bias	Studies included were 6 RCTs published between 1989 and 2010; reported differences between HBO_2 and NBO for neuropsychiatric outcomes (16.2% versus 16.5%; RR 0.83; 95% CI 0.38 to 1.80), memory impairment (18.2% versus 23.8%; RR 0.80; 95% CI 0.43 to 1.49), difficulty concentrating (15.0% vs 18.4%; RR 0.86; 95% CI 0.55 to 1.34), and disturbed sleep (14.7% versus 16.2%, RR 0.91; 95% CI 0.59 to 1.39); for delayed sequelae DNS (25% versus 31.1%; RR 0.35; 95% CI 0.02 to 5.97)	Starts as a Design 1; however, there was a high degree of heterogeneity, and the studies demonstrated conflicting results; furthermore, the included studies have methodologic flaws; the primary methodologic flaw was lack of blinding; 3 studies it was unclear if there was any blinding at all; 3 studies were only single blinded; of the double blinded studies; 1 had a 38% loss to follow-up; these issues are major methodologic limitations which reduced the quality assessment of the manuscript to a grade of III

Evidentiary Table (continued).

Author & Year Published	Class of Evidence	Setting & Study Design	Methods & Outcome Measures	Results	Limitations & Comments
Wang et al[27] (2019)	III	Meta-analysis of 7 RCTs comparing HBO$_2$ versus NBO and 1 session versus 2 session HBO$_2$; follow-up duration ranged from 21 days to 6 weeks; 26 to 575 patients were included in each trial (wide range); Jadad scale used to evaluate the quality, based on randomization, blinding, loss to follow-up, and the use of intention-to-treat analysis; heterogeneity - assessed using I^2 and Q statistics; publication bias assessed using funnel plots and Egger's regression intercept	Inclusion criteria: RCTs where outcomes were complete recovery, moderate sequelae, severe sequelae, all-cause death, asthenia, headache, memory impairment, disturbed sleep, difficulty in concentrating, visual disturbances, behavioral impairment, resumption of former activity, and neuropsychologic subset scores (including block design, trail making, digit span, and digit symbol)	N=2,023 patients; 7 studies no significant difference between HBO$_2$ versus NBO for full recovery, moderate sequelae, severe sequelae, all-cause death, asthenia, headache memory impairment, disturbed sleep, difficulty in concentrating, visual disturbances, behavioral impairment, or resumption of former activity; neuropsychologic scores: block design weighted mean difference 3.95, 95% CI 2.99 to 4.9; trail making weighted mean difference 3.03, 95% CI 1.1 to 4.96, but no significant difference for digit span or digit symbol	Starts as Design 1, large variation from 26 to 575 patients; outcomes were assessed in a relatively short timeframe (21 days to 6 weeks) when neurocognitive outcomes may not be apparent; normobaric group also includes high flow and oxygen mask, not just room air or simple nasal cannula; visual disturbance and behavioral impairment were too heterogeneous to combine (but they did); Jadad scale (0 to 5) is simplistic, may have inter-rater reliability issues and is based on blinding, randomization, and withdrawals/loss-to-follow-up, but not allocation concealment, which Cochrane views as critical to assess bias

ADL, activities of daily living; *CI*, confidence interval; *HBO₂*, hyperbaric oxygen; *NBO*, normobaric oxygen therapy; *NNT*, number needed to treat; *RCT*, randomized controlled trial; *RR*, risk ratio.